Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22227216 | 0.87 | MAP2K1 (0.47) | MAP2K1CNR2NPC1RAB9AKMT2A | |
| SCHEMBL7982043 | 0.85 | NPC1 (0.64) | CNR2NPC1RAB9AALDH1A1MAPK14 | |
| SCHEMBL14720615 | 0.83 | DRD2 (0.50) | MAP2K1CNR2NPC1RAB9AKMT2A | |
| SCHEMBL12121083 | 0.82 | CNR2 (0.55) | MAP2K1CNR2NPC1RAB9AMAPK14 | |
| SCHEMBL26838419 | 0.81 | TMEM97 (0.59) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| Acetic Acid SCHEMBL6454337 | 0.80 | NPC1 (0.59) | MAP2K1CNR2NPC1RAB9AALDH1A1 | |
| SCHEMBL16564432 | 0.79 | POLB (0.54) | KMT2AMEN1POLBHPGDDRD2 | |
| SCHEMBL5633653 | 0.79 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL14720296 | 0.78 | MAP2K1 (0.43) | MAP2K1CNR2NPC1RAB9AKMT2A | |
| SCHEMBL29857237 | 0.78 | ALDH1A1 (0.56) | CNR2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894481-A | Nitrogen-containing heteroaryl compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-7208629-B2 | 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-04-24 | — | — | US | disclosed |
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1435936-A1 | 5'-CARBAMOYL-1,1-BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032972-A1 | 5’-CARBAMOYL-1,1-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK4, GRK4, NR4A1 | MAP2K1 443/4885CNR2 25/4885NPC1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.